- Home
- ICON vs GTBP Comparison
ICON vs GTBP Comparison
Compare ICON & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- GTBP
- Stock Information
- Founded
- ICON 2023
- GTBP 1965
- Country
- ICON Greece
- GTBP United States
- Employees
- ICON N/A
- GTBP N/A
- Industry
- ICON
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- GTBP Health Care
- Exchange
- ICON Nasdaq
- GTBP Nasdaq
- Market Cap
- ICON 4.7M
- GTBP 5.5M
- IPO Year
- ICON 2024
- GTBP N/A
- Fundamental
- Price
- ICON $2.21
- GTBP $0.80
- Analyst Decision
- ICON Strong Buy
- GTBP Strong Buy
- Analyst Count
- ICON 1
- GTBP 1
- Target Price
- ICON $4.50
- GTBP $11.00
- AVG Volume (30 Days)
- ICON 37.5K
- GTBP 449.7K
- Earning Date
- ICON 09-10-2025
- GTBP 11-13-2025
- Dividend Yield
- ICON 426.34%
- GTBP N/A
- EPS Growth
- ICON N/A
- GTBP N/A
- EPS
- ICON N/A
- GTBP N/A
- Revenue
- ICON $6,137,000.00
- GTBP N/A
- Revenue This Year
- ICON $94.05
- GTBP N/A
- Revenue Next Year
- ICON $18.81
- GTBP N/A
- P/E Ratio
- ICON N/A
- GTBP N/A
- Revenue Growth
- ICON 25.60
- GTBP N/A
- 52 Week Low
- ICON $1.60
- GTBP $0.63
- 52 Week High
- ICON $130.80
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- ICON 51.92
- GTBP 30.54
- Support Level
- ICON $1.87
- GTBP $0.78
- Resistance Level
- ICON $2.37
- GTBP $0.85
- Average True Range (ATR)
- ICON 0.11
- GTBP 0.09
- MACD
- ICON 0.04
- GTBP 0.03
- Stochastic Oscillator
- ICON 67.00
- GTBP 47.22
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.